-
Demethyleneberberine Arrests NSCLC Through c-Myc/HIF-1α
2026-09-15
The reference study identifies Demethyleneberberine (DMB) as an inhibitor of NSCLC growth that connects c-Myc/HIF-1α signaling with cell-cycle arrest and cellular senescence. Its combination of phenotypic assays, RNA sequencing, pathway rescue, and xenograft testing provides a useful preclinical framework, while the model limitations leave pharmacology and clinical translation unresolved.
-
ER-Targeted Peptide Self-Assembly in Cancer
2026-09-15
The reference study developed an alkaline phosphatase-responsive peptide that self-assembles at the endoplasmic reticulum through an integrated phosphotyrosine trigger and p-toluenesulfonamide targeting group. In cancer cells with elevated alkaline phosphatase, this design promoted ER stress, apoptosis, and necroptosis while reducing the concentration required for effective cell-fate modulation relative to non-targeted intracellular self-assembly.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-14
A 2026 FASEB Journal study developed chemically modified p21 mRNA packaged in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21, inhibited cell-cycle progression and tumor growth, and produced bladder-localized expression with limited systemic distribution in preclinical models.
-
Canagliflozin and Renal Mitochondrial Remodeling
2026-09-14
The 2025 reference study shows that Canagliflozin reshapes proximal tubular cell mitochondria in hypertensive–diabetic mice, with stronger structural and bioenergetic effects in males than females. Its findings extend interpretation of SGLT2 inhibition beyond renal glucose reabsorption inhibition and support mitochondrial remodeling as a possible component of kidney protection.
-
PYR-41: E1 Inhibition for Ubiquitination Research
2026-09-13
PYR-41 enables researchers to test how E1-dependent ubiquitination controls protein stability, NF-κB responses, and infection-associated signaling. Its upstream activity creates a useful contrast with downstream proteasome assays, while careful dose, solvent, and viability controls help manage its documented off-target potential.
-
O-GlcNAcylation Rewires Glycolysis in Bone Formation
2026-09-12
The reference study identifies O-GlcNAcylation as a critical mediator of Wnt-driven osteogenesis, linking Wnt signaling to aerobic glycolysis through stabilization of PDK1 at Ser174. Its combination of lineage-specific genetic analysis, metabolic assessment, and bone-healing models provides a framework for studying how nutrient flux and post-translational modification regulate bone formation.
-
CHIR 99021 Trihydrochloride for Organoids
2026-09-12
Learn how CHIR 99021 trihydrochloride can tune GSK-3 activity in organoid workflows while preserving a practical path from stem-cell expansion to lineage diversification. This guide combines reference-backed biology with dose selection, washout logic, metabolic-model applications, and troubleshooting safeguards.
-
Alfuzosin HCl: Assay Design for BPH Research
2026-09-11
Alfuzosin HCl links α1-adrenoceptor pharmacology with practical analytical workflows for benign prostatic hyperplasia research. This guide explains how micellar spectrofluorimetry, functional tissue assays, formulation testing, and matrix controls can be integrated without confusing analytical sensitivity with biological selectivity.
-
Torin2: Reading mTOR-Driven Cell Death
2026-09-11
Torin2 is a potent mTOR inhibitor for separating pathway suppression, growth arrest, and apoptosis in cancer research. This article connects Torin2 assay design with new evidence that drug-induced cell death can reflect active signaling rather than passive loss of transcription.
-
Deferiprone for Reliable Iron-Stress Assays
2026-09-10
This scenario-based guide explains how Deferiprone, SKU B1723, can support interpretable cell viability, proliferation, and cytotoxicity studies through controlled iron depletion. It connects iron-chelation chemistry with practical formulation, optimization, data interpretation, and supplier-selection decisions.
-
MK-1775: Measuring Wee1 Checkpoint Response
2026-09-10
Explore how MK-1775, a selective Wee1 kinase inhibitor, links G2 checkpoint abrogation to more rigorous measurements of growth inhibition and cell killing. This assay-centered guide integrates Wee1 pharmacology with insights from a doctoral study on interpreting anticancer drug responses in vitro.
-
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-09-09
Masitinib (AB1010) is a DMSO-compatible phenylaminothiazole-type tyrosine kinase inhibitor for targeted KIT and PDGFRα/β experiments, including cancer biology, mast cell, and inflammatory disease models. This guide explains how to formulate, control, and interpret assays when aqueous or ethanol-based workflows, broad kinase inhibition, or direct clinical application are not appropriate.
-
EZ Cap™ Mouse IL-12 mRNA: Assay Design
2026-09-08
EZ Cap™ Mouse IL-12 mRNA (m1Ψ) enables controlled studies of IL-12 expression, immune activation, and delivery performance. This guide connects transcript engineering with practical assay decisions and emerging extrahepatic mRNA delivery research.
-
Puromycin Aminonucleoside: Nephrology Models
2026-09-08
Puromycin aminonucleoside is the aminonucleoside moiety of puromycin and a widely used nephrotoxic agent for experimental podocyte injury and proteinuria induction in animal models. Its strongest use is mechanistic modeling of glomerular barrier damage, while supplier-reported uptake and cytotoxicity data help define in vitro assay conditions.
-
Deferiprone: Iron Stress as a Translational Lever
2026-09-07
Deferiprone is more than an iron-chelation reagent: it is a controlled perturbation tool for mapping how iron availability reshapes proliferation, metabolism, inflammation, oxidative stress, and apoptosis. This article connects enterocyte findings with cancer biology, doxorubicin-response studies, and cerebral vasospasm treatment research while outlining a rigorous workflow for translational experiments.